CXCL9 and lung cancer: Moreover, in “cold-type” lung cancer, epigenetic regulators can activate chemokines such as CXCL9 and CXCL10, transforming it into a “hot-type” tumor and significantly enhancing the response rate to PD-1/PD-L1 inhibitors.